Patents by Inventor Cyril Berthet

Cyril Berthet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiolabeled macrocyclic EGFR inhibitor
    Patent number: 10716869
    Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 21, 2020
    Assignee: Oncodesign SA
    Inventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen, Gilles Voit, Jean-Bernard Deloye
  • RADIOLABELED MACROCYCLIC EGFR INHIBITOR
    Publication number: 20190054197
    Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 21, 2019
    Applicant: Oncodesign SA
    Inventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen